20 Jan AorticLab S.r.l. Announces Clear Victory Before the European Unified Patent Court in Litigation Brought by Emboline, Inc.

AorticLab’s FLOWer™ embolic protection device has received full clearance following the Unified Patent Court’s clear dismissal of Emboline’s infringement claims regarding European Patent EP 2129425, ensuring continued patient access to its innovative technology

COLLERETTO GIACOSA, Italy, Jan. 20, 2026 /PRNewswire/ — AorticLab S.r.l. today announce sits clear victory before the Court of First Instance of the Unified Patent Court (UPC), Local Division Munich, following the comprehensive dismissal of the patent infringement action filed by Emboline, Inc. concerning the European Patent EP2129425.

In its judgement of 13 January 2026, the Court found that AorticLab’s FLOWer™ embolic protection device does not infringe the asserted patent and dismissed all Emboline’s claims.

The primary consequence of the UPC verdict (which remains subject to a possible appeal within the statutory time limits) is to enable European patients undergoing interventional cardiology procedures to have access to a safer outcome, AorticLab’s FLOWer™ being the only full body anti-embolic protection device available on the European market.

AorticLab remains committed to the advancement of embolic protection through a combination of rigorous engineering and clinical and scientific excellence.

AorticLab was represented throughout the UPC proceedings by an experienced international legal team, comprising Sabine Agé, attorney-at-law at HOYNG ROKH MONEGIER Law Firm, André Roland, Patent and Trademark attorney at ANDRÉ ROLAND SA – IP Attorneys & Services and Corrado Lucchetti, attorney-at-law at LRV LEGAL.